Glenmark's Profit Surge Signals Strong Turnaround
The company's first-quarter profit jumped nearly tenfold year-on-year, while revenue grew by a solid 23.1%.
Glenmark Pharmaceuticals reported a staggering 928% year-on-year profit growth for Q1 FY27, driven by a strong revenue increase and a significant expansion in net profit margin.
Glenmark Pharmaceuticals has delivered a powerful earnings turnaround in the first quarter of FY27. Profit after tax surged by 928% year-on-year, a dramatic recovery from a low base, while revenue grew by a healthy 23.1%. This performance was supported by a significant expansion in profitability, with the net profit margin reaching 12.0%.
The company's momentum is clear when looking at the sequential improvement. Revenue grew 6.6% from the previous quarter, while profit jumped 60.2%. This indicates that the operational strength seen in the annual results is carrying forward. The trailing-twelve-month (TTM) net profit margin stands at 10.1%, showing the company is sustaining healthier profitability levels overall.
A look at the last five quarters reveals the scale of the recovery and the recent positive trend.
Revenue & profit
Revenue (₹ Cr.)
Profit (₹ Cr.)
Net Profit Margin (%)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Revenue (₹ Cr.) | 4,018.48YoY +23% | 3,770.59 | 3,264.44 |
| Profit (₹ Cr.) | 482.83YoY +928% | 301.32 | 46.97 |
| Net Profit Margin (%) | 12.0YoY +757% | 8.0 | 1.4 |
Key Points
- The company maintains a robust balance sheet with zero debt on its books.
- Returns on capital remain strong, with an ROCE of 20.35%.
- The stock has delivered impressive long-term returns, with a 42.7% CAGR over the past three years, though it now trades at a premium to the industry average.
With profitability now firmly re-established, the focus shifts to whether Glenmark can maintain this elevated margin profile alongside consistent top-line growth in the coming quarters.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.